Study S000154

Semaglutide for Metabolic and Adiposity-Related Targets in Youth With Autism Spectrum Disorder (SMART-ASD)

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07770152
Acronym: GLP1
Study type: INTERVENTIONAL
Allocation: NON_RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: NOT_YET_RECRUITING
Enrollment: 42
Start: 2026-09-01
Primary completion: 2028-09-01
Lead sponsor: Children's Hospital Medical Center, Cincinnati
Conditions: Autism Spectrum Disorder; Obesity
Interventions: DRUG:Glucagon-like peptide-1 receptor agonist：Semaglutide; BEHAVIORAL:Lifestyle Management (LSM) Counseling
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Number of Participants With Percent Change in BMI (kg/m2) [12 months]
Number of Participants With Change in Skeletal Muscle Mass (SMM) [12 months]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.